Search results

Skip to results

Type

Type

Last updated

Last updated

Guidance programme

Showing 1 to 13 of 13 results for cg181

  1. Cardiovascular disease. Patient decision aid on should I take a statin?

    risk assessment and reduction, including lipid modification. NICE guideline CG181 Evidence review C statins: efficacy and adverse...

  2. Re-engineering the Post-Myocardial Infarction Medicines Optimisation Pathway

    including lipid modification (CG181)

    Shared learning
    Last updated
    6 January 2021

  3. Systematic case finding of people with hypertension

    diagnosed for diagnosis as set out in CG127 and QRISK assessment as set out in CG181. After 12 months, there was an increase in 6,167...

    Shared learning
    Last updated
    14 November 2019

  4. Innovative Medicines Optimisation Clinic for PCSK9 inhibitors & Statin Intolerance

    including lipid modification (CG181)

    Shared learning
    Last updated
    27 September 2019

  5. Research recommendations

    CG181/1 | What is the effectiveness of age alone and other routinely available

  6. What is the clinical effectiveness and rate of adverse events of statin therapy using atorvastatin 20 mg per day compared with atorvastatin 40 mg per day and atorvastatin 80 mg per day in people without established CVD?

    Recommendation ID CG181/5 Question What is the clinical effectiveness and rate of adverse events of statin therapy using atorvastatin 20

    Research recommendation
    Published
    9 June 2015

  7. What is the improvement in the cost-effectiveness metrics for statin therapy in reducing CVD that can be obtained when using a complete individual patient-based outcomes meta-analysis data set compared with using published outcomes data?

    Recommendation ID CG181/2 Question What is the improvement in the cost-effectiveness metrics for statin therapy in reducing CVD that can

    Research recommendation
    Published
    9 June 2015

  8. What is the effectiveness of statins and/or other LDL-cholesterol-lowering treatment in people with type 1 diabetes?

    Recommendation ID CG181/4 Question What is the effectiveness of statins and/or other LDL-cholesterol-lowering treatment in people with

    Research recommendation
    Published
    9 June 2015

  9. What is the effectiveness of statin therapy in older people?

    Recommendation ID CG181/3 Question What is the effectiveness of statin therapy in older people? Any explanatory notes(if applicable)

    Research recommendation
    Published
    9 June 2015

  10. What is the effectiveness of age alone and other routinely available risk factors compared with the formal structured multifactorial risk assessment to identify people at high risk of developing CVD?

    Recommendation ID CG181/1 Question What is the effectiveness of age alone and other routinely available risk factors compared with the

    Research recommendation
    Published
    9 June 2015

  11. Cardiovascular disease: risk assessment and reduction, including lipid modification (CG181)

    This guideline has been updated and replaced by NICE guideline NG238.

    Clinical guideline
    Published
    18 July 2014

  12. Lipid modification: Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease (CG67)

    This guidance has been updated and replaced by NICE guideline CG181.

    Clinical guideline
    Published
    28 May 2008

  13. Statins for the prevention of cardiovascular events (TA94)

    This guidance has been updated and replaced by NICE guideline CG181.

    Technology appraisal guidance
    Published
    25 January 2006